Skip to the main content.
HUB of
Biotherapeutic
Intelligence™
Antibody Discovery Services
Overview
Target Analysis & Immunization
Antibody Discovery & Characterization
Developability Profiling
Optimization & Engineering
Preclinical Services
Protein Manufacturing
Overview
 
Catalog Products
Online Store
See our latest upcoming event
Tell me moreto Events
 
Connect with IPA

Contact usto Contact
Follow us on LinkedInto LinkedIn

HUB of
Biotherapeutic
Intelligence™
AI Technology
LENSai Applications
The LENSai Difference
See our latest upcoming event
Tell me moreto Events
 
Connect with IPA

Contact usto Contact
Follow us on LinkedInto LinkedIn

HUB of
Biotherapeutic
Intelligence™
Applications
Insights
See our latest upcoming event
Tell me moreto Events
 
Connect with IPA

Contact usto Contact
Follow us on LinkedInto LinkedIn

HUB of
Biotherapeutic
Intelligence™
Resources
Antibody Discovery Resources
AI Technology Resources
IPA Collective
Resource Spotlight
See our latest upcoming event
Tell me moreto Events
 
Connect with IPA

Contact usto Contact
Follow us on LinkedInto LinkedIn

HUB of
Biotherapeutic
Intelligence™
Company
Overview
Leadership
Investor Relations
Careers
Locations
Contact Us
News
News & Press Releases
Events
See our latest upcoming event
Tell me moreto Events
 
Connect with IPA

Contact usto Contact
Follow us on LinkedInto LinkedIn

In the News

Contact Us

IPA News
June 10th, 2024
BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery
-BioStrand now offers a Customizable Application Programming Interface (API) with its new software offering, LENSai API, featuring the ability to integrate sizable databases and electronic health records with large language models. ...
March 28th, 2024
InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications
VICTORIA, BRITISH COLUMBIA (CANADA), March 28, 2024 – IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), InterSystems, a creative data technology provider dedicated to helping customers solve their most critical...
March 20th, 2024
IPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI Developments
Significant throughput of LSA to advance IPA’s diversity- and data-driven drug development and to enrich LENSai™. VICTORIA, BRITISH COLUMBIA (CANADA), March 20, 2024 – IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), ...
March 27th, 2023
European Patent Office to Grant BioKey’s Patent Application for Foundational HYFT® Technology
Company Received Official Notice from the European Patent Office (EPO) for the Decision to Grant its Patent Application on April 5th, 2023. The Patent was Initially Filed February 7th, 2020. Patent Application Covers a Method to Efficiently...